RxDoctor Payments Data

David Weiser, MD

Ophthalmology · Melbourne, FLNPI 1932150455

Payments from drug & device makers

$990in general payments, 2019–2025

Across 29 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$206
  • Alcon$169
  • Amgen$143
  • Glaukos Corporation$122
  • AbbVie$68
  • Bausch & Lomb Americas Inc.$68
  • plus $215 from 7 others

What the payments were for

  • Speaking & faculty fees$323%
  • Food & beverage$95797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$990 in reported general payments places this provider in the 30th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$1,001,741
Medicare patients
2,118
Services billed
6,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine40$45,135
LumiganBimatoprost45$25,145
Prednisolone Acetate617$20,345
Timolol Maleate361$16,279
IlevroNepafenac42$15,220
Latanoprost849$11,133
Travoprost41$10,721
RhopressaNetarsudil Mesylate29$9,807
CombiganBrimonidine Tartrate/Timolol22$8,397
TyrvayaVarenicline Tartrate12$8,104
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat330$8,061
Difluprednate70$7,508
XiidraLifitegrast12$7,152
Brimonidine Tartrate188$2,857
Ketorolac Tromethamine110$2,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$68$78,677107 claims
Oyster Point Pharma, Inc.Tyrvaya$16$8,10412 claims
Bausch & Lomb Americas Inc.Xiidra$68$7,15212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →